Table 1.
Clinical and pathological characteristics of lung cancer patients with c-Met overexpression.
| Feature | Patients (n) | (%) | c-Met OE (n) | % | P value |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 63 | 43.2 | 30 | 47.6 | >0.05 |
| Female | 83 | 56.8 | 44 | 53.0 | |
| Histopathological subtypes | |||||
| SCLC | 14 | 9.6 | 7 | 50.0 | >0.05 |
| NSCLC | 132 | 90.4 | 67 | 50.8 | |
| Clinical stage | |||||
| I | 32 | 21.9 | 11 | 34.4 | <0.05 |
| II | 70 | 47.9 | 29 | 41.4 | |
| III | 28 | 19.2 | 20 | 71.4 | |
| IV | 16 | 11.0 | 14 | 87.5 | |
| Lymph node | |||||
| Negative | 102 | 69.9 | 50 | 49.0 | >0.05 |
| Positive | 44 | 30.1 | 24 | 54.5 | |
| Metastasis | |||||
| M0 | 128 | 87.7 | 65 | 50.8 | >0.05 |
| M1 | 18 | 12.3 | 9 | 50.0 | |
| Differentiation | |||||
| Well | 28 | 19.2 | 9 | 32.1 | <0.01 |
| Moderate | 79 | 54.1 | 33 | 41.8 | |
| Poor | 39 | 26.7 | 32 | 82.1 |
SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; OE: overexpression.